# Stretching Doses to Save Money

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-11-02

Canonical page: https://glpwatchdog.org/research/stretching-doses-to-save-money

> At list prices above a thousand dollars a month, people stretch these drugs. Two papers argue fortnightly dosing keeps most of the weight loss, on a mathematical model and a case series of two patients.

## Key points

- The entire clinical evidence base is a case series of TWO patients.
- The '75% of weight loss at fortnightly dosing' figure is a SIMULATION output, never measured.
- The pharmacology is sound: with a week-long half-life, a dose is still half present seven days later.
- 'Increase the dose size' assumes a dose that exists, but pens come in fixed strengths.
- The tirzepatide model was adapted from the semaglutide one, not built independently.
- Dose reduction and handing over to another agent DO have randomized evidence.

List prices run past a thousand dollars a month, and even the manufacturers’ own cash prices reach several hundred at maintenance doses, so people stretch these drugs, injecting every two weeks instead of every one. Two published papers argue this may keep most of the weight loss.[1][2] The pharmacological reasoning is sound, and it helps to understand it. The evidence behind it is **a mathematical model and a case series of two people**, and you should know that before deciding anything.

> **This page explains what has been published. It is not a schedule and not a recommendation.** Changing how often you inject a prescription medicine is a decision for the person who prescribed it, and the papers below describe their own approach as off-label and requiring validation. Stretching the interval, stepping down to a lower labeled dose, and dosing below the labeled range are three different things that get confused constantly; [every-other-week dosing](https://glpwatchdog.org/research/every-other-week-dosing) separates them.

## Why the idea is not silly

The intuition that halving your doses halves the effect is wrong, and understanding why is useful whether or not you ever change anything.

Semaglutide has an elimination half-life of roughly a week. That means a dose is still half present seven days later, and with weekly dosing the drug [accumulates to a plateau](https://glpwatchdog.org/research/does-your-glp1-wear-off-mid-week) over several weeks. Stretch to fortnightly and you do not drop to zero between doses; you settle at a lower plateau with wider swings. Since the relationship between drug level and appetite suppression is not a straight line, a lower plateau does not translate into a proportionally smaller effect.

> With a half-life of roughly a week, a dose is still half present seven days later.

That is the whole argument, and it is a reasonable one. So far, though, it remains an argument rather than a measurement.

## What the two papers actually contain

*The published evidence for less frequent dosing, in full.[1][2]*

| Paper | What it is | What it reports |
| --- | --- | --- |
| Diabetes, Obesity and Metabolism, 2025[1] | **Mathematical modeling and simulation** of regimens the authors state have not yet been studied clinically | Fortnightly dosing maintains roughly 75% of weight loss; with an appropriate increase in dose size, close to 100% |
| Obesity, 2025[2] | **A case series of two patients**, plus simulated virtual patients | Both patients maintained significant weight loss; the majority of weight loss persists at 2, 3, or perhaps 4 weeks between doses |

> **Read the middle column again.** The 75% figure has never been measured in a person; a simulation produced it. The paper that describes itself as supplying clinical evidence supplies two patients. There is no randomized trial, no cohort study, and no comparison group anywhere in this literature.

Both papers come from the same research group, which is normal for a new line of work and means these are not two independent confirmations of anything.

A 2026 case series from an unrelated group reports the same practice, and is covered separately in [every-other-week dosing](https://glpwatchdog.org/research/every-other-week-dosing).[3] Independent authors observing it adds something, but it does not change the shape of the evidence, which remains a handful of patients observed rather than randomized.

## What the models leave out

- **“An appropriate increase in dose size” assumes a dose you can deliver.** Pens and vials come in fixed strengths. The regimen that preserves 100% of the effect in a simulation may not exist as a physical object.
- **The tirzepatide modeling is borrowed.** The authors built it by taking the semaglutide pharmacodynamic model and reparameterizing it to fit tirzepatide data. The result is a fitted adaptation, not an independent model of that drug.
- **Tolerability is not modeled.** Titration schedules exist because larger jumps in exposure cause more nausea and vomiting. A bigger, less frequent dose is exactly the pattern those schedules are designed to avoid, and nothing here tested it.
- **Nothing addresses diabetes.** These are weight models. Someone whose glucose control depends on steady drug levels is in a different situation entirely.

## A drug built for the interval, tested against a weekly one

The strongest evidence that fortnightly dosing can work is not about stretching an existing drug at all. Bofanglutide is engineered for a two-week interval, and a phase 2b trial put it head to head against weekly semaglutide in 272 people with type 2 diabetes.[4]

*HbA1c change at 24 weeks. Q2W is once every two weeks; QW is weekly.[4]*

| Arm | HbA1c change | vs semaglutide |
| --- | --- | --- |
| Bofanglutide 12 mg Q2W | −1.87% | −0.27% (−0.61 to −0.08) |
| **Bofanglutide 18 mg Q2W** | **−2.28%** | **−0.68% (−1.04 to −0.33)** |
| Bofanglutide 24 mg Q2W | −1.94% | −0.34% (−0.70 to 0.02) |
| Bofanglutide 24 mg QW | −2.32% | −0.72% (−1.08 to −0.36) |
| Semaglutide 1 mg QW | −1.60% | — |

A fortnightly injection beat a weekly one. That shows the interval is achievable when the molecule is designed for it, with a half-life and a dose chosen to hold levels across fourteen days.

> **Three things stop it transferring to stretching a drug you already have.** The comparator was semaglutide at *1 mg*, the diabetes dose rather than the 2.4 mg weight dose. The trial was open-label, 24 weeks, and entirely in Chinese participants, limitations the authors state themselves. And gastrointestinal side effects ran 81.8% to 87.3% on bofanglutide against 51.9% on semaglutide.

The doses also do not order cleanly. Eighteen milligrams outperformed twenty-four on the same schedule (−2.28% against −1.94%), and the confidence interval for the 24 mg fortnightly arm crossed zero.

## The public health argument, separately

The modeling paper makes a second claim, and it should be kept apart from the first. Given a fixed national budget, it simulates treating a certain number of people weekly against treating twice as many fortnightly, and finds the second reduces population obesity and mortality considerably more.

That is an argument about resource allocation, not about any individual’s treatment. It does not need fortnightly dosing to be *as good*, only better than nothing, which is a far weaker requirement. It is an interesting policy point, and it rests on the same unvalidated model.

## If cost is the reason you are reading this

Cost ending treatment is one of the most common ways these drugs fail, and it is a real problem that deserves better answers than a spreadsheet. The routes with evidence behind them are different from this one.

- **A lower labeled dose** has randomized evidence: reducing rather than stopping held much of the loss, covered in [the maintenance trial](https://glpwatchdog.org/research/tirzepatide-maintenance-dose-trial).
- **Handing over to a different agent** was tested directly: a pill maintained 79.3% of the reduction against 37.6% on placebo, in [the oral handover](https://glpwatchdog.org/research/a-pill-to-hold-what-the-injection-lost).
- **What people actually do after stopping**, and how little the average person regained, is in [its own piece](https://glpwatchdog.org/research/what-people-actually-do-after-stopping).
- **A cheaper approved product** may already exist for you. In October 2026 the Wegovy pill cost $299 a month at its 25 mg maintenance dose through Novo’s own pharmacy, and Lilly sold Foundayo from $149 a month at the starting dose.[5][6] Switching drugs is your prescriber’s call, but each of those has trial evidence behind it at the dose you would take.
- **Current prices by seller** are on the [price tracker](https://glpwatchdog.org/price-tracker), dated.

One catch with the lower-dose route: at many sellers it does not change the bill. [Prime Health](https://glpwatchdog.org/reviews/prime-health), [Medi-Weightloss](https://glpwatchdog.org/reviews/medi-weightloss) and [LifeRx.md](https://glpwatchdog.org/reviews/liferx) charge one price at every dose, and so do [New Wave Health](https://glpwatchdog.org/reviews/new-wave-health) and [Collective](https://glpwatchdog.org/reviews/collective), though Collective adds a required annual membership on top. [altRX](https://glpwatchdog.org/reviews/altrx) lists one price at every dose for both its compounded semaglutide and its compounded tirzepatide, and [TrimRx](https://glpwatchdog.org/reviews/trimrx) promises that its compounded price stays the same as the dose changes. [Unique Physique](https://glpwatchdog.org/reviews/unique-physique) is a partial exception, with a cheaper flat tier for doses up to 2.5 mg and a higher one for any dose. [UrWay Health](https://glpwatchdog.org/reviews/urway-health) has a similar split for compounded tirzepatide, $299 a month from 1.5 mg to 9 mg and $399 from 11 mg to 13.5 mg, while its semaglutide is $249 a month at any dose. [Brello Health](https://glpwatchdog.org/reviews/brello-health) goes a step further and promises no increase at renewal as well as none when the dose changes. Where the price follows the dose, stepping down does lower it: at [Optimize HP](https://glpwatchdog.org/reviews/optimize-hp), compounded tirzepatide with B12 on the 3-month plan is $199 every 4 weeks at 15 mg a week and $149 at 10 mg.

[Eden](https://glpwatchdog.org/reviews/eden) works the same way on its price pages, which promise one charge at every dose of compounded semaglutide or tirzepatide. Read its terms as well before counting on that figure: they still describe a monthly membership billed on top of the medication. [Trinity Meds](https://glpwatchdog.org/reviews/trinity-meds) lists one flat monthly price for compounded semaglutide and another for compounded tirzepatide, each the same at every dose. [RenewMD](https://glpwatchdog.org/reviews/renewmd) keeps each 28-day price the same at every dose too: $249 for the semaglutide injection and $339 for tirzepatide. At [Rift](https://glpwatchdog.org/reviews/rift) the price also stays the same at every dose, but it changes with the pharmacy you pick and the length of the plan.

Two other formats come up in the same conversation. [Chronos Body Health & Wellness](https://glpwatchdog.org/reviews/chronos-bhw) sells compounded drugs as packages rather than a monthly plan, which it says last two and a half to three months at the starting dose. [One80Rx](https://glpwatchdog.org/reviews/one80rx) and Chronos also offer [microdose plans](https://glpwatchdog.org/research/glp1-microdosing-price-check); a microdose sits below the labeled range, so it is not the same as the lower labeled dose in the maintenance trial. [SkinnyRx](https://glpwatchdog.org/reviews/skinnyrx) also lists a microdose option for its compounded semaglutide and tirzepatide injections, advertised at $99 for the first month.

The fortnightly idea may well turn out to be right. But someone deciding today is deciding on a model and two people, which is materially different from deciding on a trial.

## Frequently asked questions

### Can I inject my GLP-1 every two weeks to save money?

That is a question for your prescriber. Two published papers argue it may preserve most of the weight loss, but their evidence is a mathematical model and a case series of two patients. There is no randomized trial, no cohort and no comparison group.

### Why would less frequent dosing keep working at all?

Semaglutide's half-life is roughly a week, so a dose is still half present seven days later and the drug accumulates to a plateau. Dosing fortnightly settles at a lower plateau rather than dropping to zero, and the relationship between drug level and appetite suppression is not a straight line.

### Where does the '75% of weight loss' figure come from?

A simulation. It is a model output for a regimen the authors state has not been studied clinically, not a measurement from any patient.

### The papers mention increasing dose size. Does that fix it?

In the model, close to 100% of the effect is preserved if the less frequent dose is larger. Pens and vials come in fixed strengths, so the regimen that works in the simulation may not be deliverable. Larger jumps in exposure are also what titration schedules exist to avoid.

### What options have real evidence behind them?

Reducing to a lower labeled dose and handing over to another agent have both been tested in randomized trials. Neither is a stretched schedule, and both beat stopping outright.

## References

1. Cengiz A, Wu CC, Lawley SD. Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy. Diabetes, Obesity and Metabolism. 2025. PMID: 39950222. https://pubmed.ncbi.nlm.nih.gov/39950222/
2. Wu CC, Cengiz A, Lawley SD. Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy. Obesity. 2025. PMID: 40415172. https://pubmed.ncbi.nlm.nih.gov/40415172/
3. Wong M, Wu A, Garhe PK, Biermann M. Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series. Obesity. 2026. PMID: 41732031. https://pubmed.ncbi.nlm.nih.gov/41732031/
4. Liu M, Cheng Z, Lu L, et al. Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes: A Phase 2b Randomized Clinical Trial. Annals of Internal Medicine. 2026. PMID: 42372276. https://pubmed.ncbi.nlm.nih.gov/42372276/
5. Novo Nordisk Wegovy® Savings Offer — self-pay pricing for the Wegovy pill, pen and Wegovy HD. novocare.com. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html
6. Eli Lilly and Company Foundayo™ — LillyDirect self-pay pricing. lilly.com, LillyDirect. 2026. https://www.lilly.com/lillydirect/foundayo

---

Cite as: GLP Watchdog, Nora Bissett, "Stretching Doses to Save Money", published 2026-08-20, updated 2026-11-02. https://glpwatchdog.org/research/stretching-doses-to-save-money

Canonical HTML page: https://glpwatchdog.org/research/stretching-doses-to-save-money

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
